Zogenix has completed enrolling patients in a second Phase 3 trial evaluating ZX008 as a treatment for Dravet syndrome epilepsy. Standard epilepsy medications are unable to counter Dravet-associated seizures, which can cause cognitive impairment and even death. Doctors usually use anticonvulsant medications for the disease, but patient outcomes remain poor. ZX008…
News
Incorporating brain activity pattern analysis in chemical compounds screenings for Dravet syndrome and other epilepsies can help predict therapies’ effectiveness and minimize chances for off-target effects. That finding comes from the study “Brain activity patterns in high-throughput electrophysiology screen predict both drug efficacies and side effects,” which was published…
News
Respiratory Impairments Common, May Increase Risk of Sudden Death in Dravet Syndrome, Study Finds
Severe respiratory abnormalities induced by seizures are common in patients with Dravet syndrome, and may increase patients’ risk of sudden unexplained death in epilepsy (SUDEP), according to a recent study. The report, “Severe Peri-Ictal Respiratory Dysfunction is Common in Dravet Syndrome,” was published in The Journal of Clinical…
This week marks the launch of the “7,000 Mile Rare Movement,” a nationwide effort to raise money for research into the 7,000 known rare diseases that afflict at least 30 million Americans. The campaign kicks off Feb. 1 and culminates with Rare Disease Day on Feb. 28. Organized by…
Topamax (topiramate, TPM) is far more effective than Onfi (clobazam, CLB) when combined with two other medications in reducing the number of seizures in an infant with Dravet syndrome, a Japanese case study shows. The study, “Marked efficacy of combined three-drug therapy (Sodium Valproate, Topiramate and Stiripentol) in a patient…
The U.S. Food and Drug Administration will give priority review to a New Drug Application that GW Pharmaceuticals submitted for its cannabis-based therapy for two difficult-to-treat epilepsies that appear in childhood. U.S. regulators” decision to review the application on an accelerated timetable follows GW’s submission of a Marketing Authorization Application to…
Sudden unexplained death in epilepsy (SUDEP) in patients with Dravet syndrome can be caused by breathing abnormalities associated with an epileptic seizure, which may slow down the heart rate and eventually lead to death, a study shows.
Recent Posts
- Faster-than-expected enrollment seen in trial testing zorevunersen for Dravet
- The little lost journal that brings back memories of our Dravet journey
- FDA grants breakthrough status to new gene therapy for Dravet syndrome
- First look at ETX101 suggests early benefits for children with Dravet
- Grief comes in waves and reminds me of the start of a long journey
- Stoke readies to meet with FDA on 4 years of zorevunersen study data
- Continuing family traditions helps keep my daughter’s memory alive
- FDA awards RMAT designation to Dravet syndrome gene therapy
- A return to homeschooling reminds me how high my daughter soared
- COULD IMPROVED SEIZURE CONTROL HELP YOUR LOVED ONE DO MORE OF WHAT THEY LOVE?